30 related articles for article (PubMed ID: 37925763)
1. Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.
Deis SM; Doshi A; Hou Z; Matherly LH; Gangjee A; Dann CE
Biochemistry; 2016 Aug; 55(32):4574-82. PubMed ID: 27439469
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment.
Wallace-Povirk A; Rubinsak L; Malysa A; Dzinic SH; Ravindra M; Schneider M; Glassbrook J; O'Connor C; Hou Z; Kim S; Back J; Polin L; Morris RT; Gangjee A; Gibson H; Matherly LH
Sci Rep; 2022 Jul; 12(1):11346. PubMed ID: 35790779
[TBL] [Abstract][Full Text] [Related]
3. Revealing tumor cells and tissues with high selectivity through folic acid-targeted nanofluorescence probes responsive to acidic microenvironments.
Li J; He H; Liu S; Li X; Wu F
Front Oncol; 2024; 14():1404148. PubMed ID: 38933449
[TBL] [Abstract][Full Text] [Related]
4. Multitargeted 6-Substituted Thieno[2,3-
Tong N; Wong-Roushar J; Wallace-Povirk A; Shah Y; Nyman MC; Katinas JM; Schneider M; O'Connor C; Bao X; Kim S; Li J; Hou Z; Matherly LH; Dann CE; Gangjee A
ACS Pharmacol Transl Sci; 2023 May; 6(5):748-770. PubMed ID: 37200803
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
Wang Y; Cherian C; Orr S; Mitchell-Ryan S; Hou Z; Raghavan S; Matherly LH; Gangjee A
J Med Chem; 2013 Nov; 56(21):8684-95. PubMed ID: 24111942
[TBL] [Abstract][Full Text] [Related]
6. Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
Golani LK; Wallace-Povirk A; Deis SM; Wong J; Ke J; Gu X; Raghavan S; Wilson MR; Li X; Polin L; de Waal PW; White K; Kushner J; O'Connor C; Hou Z; Xu HE; Melcher K; Dann CE; Matherly LH; Gangjee A
J Med Chem; 2016 Sep; 59(17):7856-76. PubMed ID: 27458733
[TBL] [Abstract][Full Text] [Related]
7. 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
Wang L; Wallace A; Raghavan S; Deis SM; Wilson MR; Yang S; Polin L; White K; Kushner J; Orr S; George C; O'Connor C; Hou Z; Mitchell-Ryan S; Dann CE; Matherly LH; Gangjee A
J Med Chem; 2015 Sep; 58(17):6938-59. PubMed ID: 26317331
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
Golani LK; Islam F; O'Connor C; Dekhne AS; Hou Z; Matherly LH; Gangjee A
Bioorg Med Chem; 2020 Jun; 28(12):115544. PubMed ID: 32503687
[TBL] [Abstract][Full Text] [Related]
9. Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
Xiang W; Dekhne A; Doshi A; O'Connor C; Hou Z; Matherly LH; Gangjee A
Bioorg Med Chem; 2019 Dec; 27(23):115125. PubMed ID: 31679978
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel tumor-targeted near-infrared probes with 6-substituted pyrrolo[2,3-d]pyrimidines as targeting ligands.
Zhang Y; Luo Z; Guo L; Zhang H; Su T; Tan Z; Ren Q; Zhang C; Fu Y; Xing R; Guo R; Shi X; Guo H; Liu Y; Wang L
Eur J Med Chem; 2023 Dec; 262():115914. PubMed ID: 37925763
[TBL] [Abstract][Full Text] [Related]
11. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Gonen N; Assaraf YG
Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318
[TBL] [Abstract][Full Text] [Related]
12. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
